Literature DB >> 32605939

Deletion of the Mitochondrial Matrix Protein CyclophilinD Prevents Parvalbumin Interneuron Dysfunctionand Cognitive Deficits in a Mouse Model of NMDA Hypofunction.

Aarron Phensy1, Kathy L Lindquist1, Karen A Lindquist1, Dania Bairuty1, Esha Gauba2, Lan Guo2, Jing Tian2, Heng Du2, Sven Kroener3.   

Abstract

Redox dysregulation and oxidative stress are final common pathways in the pathophysiology of a variety of psychiatric disorders, including schizophrenia. Oxidative stress causes dysfunction of GABAergic parvalbumin (PV)-positive interneurons (PVI), which are crucial for the coordination of neuronal synchrony during sensory and cognitive processing. Mitochondria are the main source of reactive oxygen species (ROS) in neurons and they control synaptic activity through their roles in energy production and intracellular calcium homeostasis. We have previously shown that in male mice transient blockade of NMDA receptors (NMDARs) during development [subcutaneous injections of 30 mg/kg ketamine (KET) on postnatal days 7, 9, and 11] results in long-lasting alterations in synaptic transmission and reduced PV expression in the adult prefrontal cortex (PFC), contributing to a behavioral phenotype that mimics multiple symptoms associated with schizophrenia. These changes correlate with oxidative stress and impaired mitochondrial function in both PVI and pyramidal cells. Here, we show that genetic deletion (Ppif-/-) of the mitochondrial matrix protein cyclophilin D (CypD) prevents perinatal KET-induced increases in ROS and the resulting deficits in PVI function, and changes in excitatory and inhibitory synaptic transmission in the PFC. Deletion of CypD also prevented KET-induced behavioral deficits in cognitive flexibility, social interaction, and novel object recognition (NOR). Taken together, these data highlight how mitochondrial activity may play an integral role in modulating PVI-mediated cognitive processes.SIGNIFICANCE STATEMENT Mitochondria are important modulators of oxidative stress and cell function, yet how mitochondrial dysfunction affects cell activity and synaptic transmission in psychiatric illnesses is not well understood. NMDA receptor (NMDAR) blockade with ketamine (KET) during development causes oxidative stress, dysfunction of parvalbumin (PV)-positive interneurons (PVI), and long-lasting physiological and behavioral changes. Here we show that mice deficient for the mitochondrial matrix protein cyclophilin D (CypD) show robust protection from PVI dysfunction following perinatal NMDAR blockade. Mitochondria serve as an essential node for a number of stress-induced signaling pathways and our experiments suggest that failure of mitochondrial redox regulation can contribute to PVI dysfunction.
Copyright © 2020 the authors.

Entities:  

Keywords:  NMDA receptor; electrophysiology; medial PFC; mitochondria; parvalbumin interneuron; schizophrenia

Year:  2020        PMID: 32605939      PMCID: PMC7406283          DOI: 10.1523/JNEUROSCI.0880-20.2020

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  102 in total

1.  Glutathione!

Authors:  Joseph Pizzorno
Journal:  Integr Med (Encinitas)       Date:  2014-02

2.  NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons.

Authors:  Houman Homayoun; Bita Moghaddam
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

3.  Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death.

Authors:  Christopher P Baines; Robert A Kaiser; Nicole H Purcell; N Scott Blair; Hanna Osinska; Michael A Hambleton; Eric W Brunskill; M Richard Sayen; Roberta A Gottlieb; Gerald W Dorn; Jeffrey Robbins; Jeffery D Molkentin
Journal:  Nature       Date:  2005-03-31       Impact factor: 49.962

4.  Ketamine Administration During the Second Postnatal Week Alters Synaptic Properties of Fast-Spiking Interneurons in the Medial Prefrontal Cortex of Adult Mice.

Authors:  Vivek Jeevakumar; Sven Kroener
Journal:  Cereb Cortex       Date:  2014-12-04       Impact factor: 5.357

5.  Rethinking schizophrenia.

Authors:  Thomas R Insel
Journal:  Nature       Date:  2010-11-11       Impact factor: 49.962

6.  Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts.

Authors:  C Anthony Altar; Linda W Jurata; Vin Charles; Andrew Lemire; Peng Liu; Yury Bukhman; Theresa A Young; Jeff Bullard; Hiroko Yokoe; Maree J Webster; Michael B Knable; Jeffrey A Brockman
Journal:  Biol Psychiatry       Date:  2005-07-15       Impact factor: 13.382

Review 7.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310

Review 8.  Mitochondrial medicine for neurodegenerative diseases.

Authors:  Heng Du; Shirley ShiDu Yan
Journal:  Int J Biochem Cell Biol       Date:  2010-01-11       Impact factor: 5.085

Review 9.  The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia.

Authors:  Lakshmi Rajagopal; Bill W Massey; Mei Huang; Yoshihiro Oyamada; Herbert Y Meltzer
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

10.  The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results.

Authors:  D L Braff; R Heaton; J Kuck; M Cullum; J Moranville; I Grant; S Zisook
Journal:  Arch Gen Psychiatry       Date:  1991-10
View more
  1 in total

1.  The Relationship between the Level of Anterior Cingulate Cortex Metabolites, Brain-Periphery Redox Imbalance, and the Clinical State of Patients with Schizophrenia and Personality Disorders.

Authors:  Amira Bryll; Wirginia Krzyściak; Paulina Karcz; Natalia Śmierciak; Tamas Kozicz; Justyna Skrzypek; Marta Szwajca; Maciej Pilecki; Tadeusz J Popiela
Journal:  Biomolecules       Date:  2020-09-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.